UFCC for Cardiovascular Cell Therapy Research Network

UFCC 心血管细胞治疗研究网络

• 批准号: 8332440
• 负责人: Carl J Pepine
• 金额: $ 11.6万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-01-01 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8332440
• 关键词: Acute; Acute myocardial infarction; Address; Adverse event; Animal Model; Area; Autologous; Award; Basic Science; Biological Availability; Blood Vessels; Bone Marrow Transplantation; CD34 gene; Cardiac; Cardiovascular Diseases; Cardiovascular system; Castor; Catheters; Cell Count; Cell Therapy; Cell Transplants; Cell physiology; Cells; Cessation of life; Chronic; Cicatrix; Clinic; Clinical; Clinical Protocols; Clinical Research; Clinical Research Curriculum Award; Clinical Trials; Collaborations; Committee Members; Communities; Community Practice; Contracts; Coronary; Data; Data Collection; Decision Making; Development; Development Plans; Diabetes Mellitus; Dose; Double-Blind Method; Educational workshop; Enrollment; Ensure; Epidemic; Ethnic Origin; Europe; Feasibility Studies; Florida; Fostering; Foundations; Functional disorder; Gases; Good Clinical Practice; Grant; Guidelines; Heart; Heart Diseases; Heart Transplantation; Heart failure; Hispanics; Histologic; Hypoxia; Image; Implant; Incidence; Incubated; Individual; Industry; Injection of therapeutic agent; Institutional National Research Service Award; Investigation; Label; Lead; Left Ventricular Dysfunction; Letters; Literature; Location; Measures; Medical; Metabolic syndrome; Methods; Modeling; Morbidity - disease rate; Motion; Muscle Cells; Myocardial; Myocardial Infarction; Myocardial Ischemia; Myocardium; National Heart, Lung, and Blood Institute; Office for Protection from Research Risks; Outcome; Patient Care; Patient Recruitments; Patients; Perfusion; Phase; Phenotype; Physicians; Policies; Prevalence; Prevention; Principal Investigator; Private Practice; Procedures; Process; Prophylactic treatment; Protocols documentation; Publications; Puerto Rico; Randomized; Reaction; Records; Recruitment Activity; Regenerative Medicine; Reporting; Research; Research Design; Research Personnel; Resources; Review Committee; Risk; Role; Science; Side; Site; Site Visit; Skeletal Myoblasts; Staging; Stem cells; Structure; Technical Expertise; Techniques; Technology; Testing; Therapeutic; Therapeutic Intervention; Therapeutic Studies; Time; Training; Training Programs; Translating; Translations; Transplantation; Trauma; U-Series Cooperative Agreements; United States National Institutes of Health; Universities; Ventricular Function; Work; abstracting; aging population; base; capitate bone; cell type; cost; design; diabetic; diabetic patient; disability; follow-up; human subject; implantation; improved; innovation; insight; knowledge base; meetings; member; mortality; novel; novel strategies; pre-clinical; pre-clinical research; premature; programs; protocol development; quality assurance; research clinical testing; skills; stem cell biology; symposium; working group

DESCRIPTION (provided by applicant): The long-term objective of this application is to establish a University of Florida Clinical Center (UFCC) for the Cardiovascular Cell Therapy Research Network (CCTRN). Cardiovascular (CV) cell therapy is an exciting concept for replacement of noncontractile myocardium and its blood vessels. But despite abundant preclinical and feasibility clinical studies the ability to translate these findings to improve patient outcomes has lagged. To address this need, the UFCC utilizes established UF programs in Stem Cell Biology, Regenerative Medicine, Bone Marrow Transplant Clinical Center (part of the NIH clinical research network), novel imaging resources, the Heart Transplant Program and CV Clinical Trials Program. We have a long and well documented record of successful collaboration in multicenter NHLBI and other trials to test strategies to improve cardiac perfusion or function and evaluate clinical outcomes. Our center proposes that enhancing progenitor cell function will improve cardiac function in CAD patients with heart failure and ultimately lead to improved clinical outcomes. The two UFCC protocols propose to develop cell therapy for CAD patients with left ventricular dysfunction/heart failure using direct intramural implantation by percutaneous catheter. The first of these addresses enhancing progenitor cell function in diabetic patients. The hypothesis is in that improving NO bioavailability within the CD34+ cells will enhance their inherent ability to improve myocardial function. Specific aims test whether increasing CD34+ cell numbers; endogenous NO administration to CD34+ cells; and incubating CD34+ cells under croyperserved and/or hypoxic conditions improves wall motion or perfusion abnormalities. The hypothesis in the second protocol is that patients awaiting cardiac transplantation provide a unique opportunity to investigate effects of cell therapy on function. Specific aims test whether skeletal myoblasts' (SkM) effect on ventricular function will be dependent on the presence of cells and not a reaction to the implantation process. We will determine whether there are greater numbers of surviving cells among patients treated and redosed at 3 months and will measure the effects of cell therapy using SkM co-administered with CD34+ cells optimized in Protocol 1. Since these studies will be performed in patients awaiting transplantation, studies of explanted hearts and labeled cells should yield new information on the fate and specific location of cell implants. Novel features of both protocols are that the cells will be labeled and tracked noninvasively and verified histologically in terms of cell type in the explanted hearts investigated in Protocol 2. Other unique aspects of the UFCC include the Training Core utilizing the structure available through our K30 and T32 programs in related areas and collaborations with the University of Puerto Rico and industry. This work will improve our understanding of the role of cell therapy in patients with CAD and heart failure. (End of Abstract)

描述（由申请人提供）：

项目成果

A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.

• DOI: 10.1002/ejhf.2178
• 发表时间: 2021-04
• 期刊: European journal of heart failure
• 影响因子: 18.2
• 作者: Bolli R;Mitrani RD;Hare JM;Pepine CJ;Perin EC;Willerson JT;Traverse JH;Henry TD;Yang PC;Murphy MP;March KL;Schulman IH;Ikram S;Lee DP;O'Brien C;Lima JA;Ostovaneh MR;Ambale-Venkatesh B;Lewis G;Khan A;Bacallao K;Valasaki K;Longsomboon B;Gee AP;Richman S;Taylor DA;Lai D;Sayre SL;Bettencourt J;Vojvodic RW;Cohen ML;Simpson L;Aguilar D;Loghin C;Moyé L;Ebert RF;Davis BR;Simari RD;Cardiovascular Cell Therapy Research Network (CCTRN)
• 通讯作者: Cardiovascular Cell Therapy Research Network (CCTRN)

A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction.

• DOI: 10.1016/j.mehy.2012.08.006
• 发表时间: 2012-11
• 期刊: MEDICAL HYPOTHESES
• 影响因子: 4.7
• 作者: Della Rocca, Domenico G.;Willenberg, Bradley J.;Ferreira, Leonardo F.;Wate, Prateek S.;Petersen, John W.;Handberg, Eileen M.;Zheng, Tong;Steindler, Dennis A.;Terada, Naohiro;Batich, Christopher D.;Byrne, Barry J.;Pepine, Carl J.
• 通讯作者: Pepine, Carl J.

One-year follow-up of intracoronary stem cell delivery on left ventricular function following ST-elevation myocardial infarction.

• DOI: 10.1001/jama.2013.282674
• 发表时间: 2014-01-15
• 期刊: JAMA
• 作者: Traverse JH;Henry TD;Pepine CJ;Willerson JT;Ellis SG
• 通讯作者: Ellis SG

An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats.

• DOI: 10.1016/j.ijcard.2016.06.158
• 发表时间: 2016-10-01
• 期刊: International journal of cardiology
• 影响因子: 3.5
• 作者: Rocca DG;Willenberg BJ;Qi Y;Simmons CS;Rubiano A;Ferreira LF;Huo T;Petersen JW;Ruchaya PJ;Wate PS;Wise EA;Handberg EM;Cogle CR;Batich CD;Byrne BJ;Pepine CJ
• 通讯作者: Pepine CJ

A training program in cardiovascular cell-based therapy: from the NHLBI Cardiovascular Cell Therapy Research Network.

• DOI: 10.2217/rme.14.57
• 发表时间: 2014
• 期刊: Regenerative medicine
• 影响因子: 2.7
• 作者: Petersen JW;Winchester DE;Park K;Szady AD;Della Rocca DG;Ahmed M;Tassin H;Qi Y;Pepine CJ
• 通讯作者: Pepine CJ